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The molecular explanation for these C3a effects remains controversial. Initial data suggested that C3a acts via its known G-protein coupled receptor, C3aR, expressed on the surface of hematopoietic progenitors. 1 On closer examination, follow-up studies suggested that C3a may act via a novel/alternate receptor. 3 The C5L2 receptor was proposed to mediate C3a and C3a-desArg enhancement of CXCL12-induced responses in HPCs, 3 and the presence of mRNA encoding the C5L2 receptor in murine Sca-1 þ progenitor cells supported this possibility. 3 Despite intensive studies, cellular expression and biological functions of C5L2 remain controversial. The C5L2 receptor has high-affinity binding for C5a and C5a-desArg, 4 but contradictory results exist as to whether C5L2 can bind C3a or C3a-desArg. 5, 6 It is also controversial whether the C5L2 receptor can signal upon complement fragment binding. [4] [5] [6] To address directly whether C3a and C3a-desArg enhancement of CXCL12-mediated chemotaxis is dependent on the C5L2 receptor, we compared CXCL12-mediated migration responses of Sca-1 þ progenitor cells as well as B and T cells isolated from bone marrow of C5L2 À/À knockout mice to migration responses of cells isolated from wild type mice. Bone marrow was collected by flushing femurs and tibiae with cold PBS. Mononuclear cells were separated through Lympholite-M (Cedarlane) and placed into the upper well of the Transwell chamber (Costar), either in medium alone or with 1000 ng/ml of C3a or C3a-desArg (all from Calbiochem). The lower well contained either 10 ng/ml of murine CXCL12 (Peprotech) or chemokine together with 1000 ng/ml of C3a or C3a-desArg. The same anaphylatoxin was added to both upper and lower wells of the chamber to ensure that they did not form any chemotactic gradient. Cells were allowed to migrate for 2 h at 371C. Cells that passed through the membrane to the lower well were collected and stained with antibodies recognizing progenitor cell (Sca-1), B-cell (B220) and T-cell (CD3) determinants. In some cases cells were stained with BP-1, CD24, CD43, IgM and B220 (BD-Biosciences Pharmingen) to define sequential stages of bone marrow B-cell development.
First, we determined that C3a and C3a-desArg significantly enhanced migration to suboptimal dose CXCL12 of murine BM progenitor and B and T cells from wild-type C57 mice. C3a and C3a-desArg enhanced CXCL12-mediated migration (mean7s.d., n ¼ 5) of progenitor cells from 3.172.8 to 19.77 3.2 and 15.872.6%, B cells from 1.970.9 to 27.170.6 and 23.373.6% and T cells from 5.070.4 to 20.171 and 16.271.8%, respectively (Figure 1, left panels) .
Next, we tested the effect of C3a and C3a-desArg on CXCL12 migration of cells isolated from C5L2 KO mice. Again C3a and C3a-desArg were potent enhancers of CXCL12-mediated migration of bone marrow C5L2
À/À Sca-1 þ progenitor cells, B and T 
Figure 1
C3a and C3a-desArg enhance CXCL12-mediated chemotaxis of C5L2 deficient bone marrow hematopoietic cells isolated from C5L2 knockout mice. Specific chemotaxis of bone marrow progenitor cells (upper panel), B cells (middle panel) and T cells (lower panel) isolated from wild-type or C5L2 knockout mice toward murine CXCL12 alone (10 ng/ml) or toward CXCL12 (10 ng/ml) combined with C3a or C3a-desArg protein (1000 ng/ml) is shown. CXCL12 was present in the lower well and anaphylatoxins in both upper and lower wells of the chemotactic chamber. Results are expressed as the percentage (mean7s.d., n ¼ 7, each performed in quadruplicate) of the input cells that specifically migrated to chemokine (background migration observed in the absence of chemotactic stimulus was subtracted from CXCL12-stimulated migration). Significance is indicated: n Po0.005, nn Po0.001, nnn Po0.0001, where P represents a statistical difference in migration between cells exposed to anaphylatoxins compared to the untreated cells. cells (Figure 1 ). C3a and C3a-desArg, respectively, increased migration to CXCL12 (mean7s.d., n ¼ 7) of progenitor cells from 8.173 to 2376 and 1976%, B cells from 6.271 to 24.473.6 and 17.374% and T cells from 6.572.4 to 23.373.4 and 19.671.3% (Figure 1, right panels) . The C3a induced enhancement of CXCL12 migration was statistically highly significant (Po0.0001). C3a-desArg also significantly, albeit to a slightly lower extent (Po0.001), enhanced the chemotactic response to CXCL12 of all analyzed bone marrow cells (Figure 1) . Thus, C3a and C3a-desArg-induced enhancement of hematopoietic cells migration to CXCL12 was equal for cells isolated from both WT and C5L2 KO.
Both C3a and C3a-desArg also significantly (Po0.001) enhanced migration to CXCL12 of all subsets representing sequential stages of B-cell development (pre-pro-B, pro-B, pre-B, immature and mature B), isolated from the both C5L2 KO and WT mice (Figure 2 ).
In conclusion, we present evidence that C3a/C3a-desArgmediated enhancement of hematopoietic cell migration to CXCL12 is independent of the C5L2 receptor. 
Figure 2
Anaphylatoxins enhance CXCL12-mediated chemotaxis of C5L2 deficient developing bone marrow B cells isolated from C5L2 knockout mice. Specific chemotaxis of sequential stages of B-cell development isolated from wild-type (upper panel) or C5L2 knockout (lower panel) mice toward murine CXCL12 alone (10 ng/ml) or toward CXCL12 (10 ng/ml) combined with C3a or C3a-desArg protein (1000 ng/ml) is shown. CXCL12 was present in the lower well and anaphylatoxins in both upper and lower wells of the chemotactic chamber. Results are expressed as the percentage (mean7s.d., n ¼ 5, each done in quadruplicate) of the input cells that specifically migrated to chemokine (background migration observed in the absence of chemotactic stimulus was subtracted from CXCL12-stimulated migration). Significance is indicated: n Po0.005, nn Po0.001, nnn Po0.0001, where P represents a statistical difference in migration between cells exposed to anaphylatoxins compared to the untreated cells.
